Impella in High Risk Coronary Angioplasty before TAVR

The population is aging, which is closely related with the presence of aortic stenosis. This condition, as we know, is associated with coronary artery disease (CAD) approximately in 50% of cases. In high risk surgical patients, this calls for procedures such as percutaneous coronary intervention (PCI) and transcatheter aortic valve replacement (TAVR).  

Impella

PCI with ventricular assistance devices has surged as a valid option in this scenario; however, we should note that information on this treatment strategy is limited. 

This study recruited 15 patients with severe CAD and severe aortic stenosis at high surgical risk, but the Impella failed to cross the aortic valve in 1 patient, who was excluded despite having received balloon aortic valvuloplasty.   

Mean patient age was 88, and 6 were women. Mortality STS score was 8.3%, and SYNTAX was 16. Also, 12 patients presented hypertension and 3 had diabetes. 

Cardiac parameters showed ejection fraction was 51%, aortic valve area (AVAO) 0.85 cm², and mean gradient 40 mmHg. Left ventricular end-diastolic pressure was 19 mmHg, while median pulmonary capillary wedge pressure was 17 mmHg. Five patients experienced cardiac failure with ventricular function deterioration. 

Read also: Low vs High Dose Drug Coated Balloons in Femoropopliteal Territory.

Left main PCI was performed in 6 patients, rotational atherectomy in 10, and 2 received two-vessel PCI. 

The Impella was advanced via the femoral artery in all patients, which required prior valvuloplasty in two cases. We should point out there were no vascular complications and that the Impella access site was closed with 2 Proglide devices, and the PCI access site was closed with 1 Proglide device. 

As regards complications, there were no significant adverse events after PCI. 

RRead also: Coronary Calcification: More Frequent Use of Coronary Lithotripsy as a Recommendation.

Time between Impella placement and TAVR was 25 days, on average, ranging between 10 and 35 days. 

As regards TAVR, all patients received a Sapien valve successfully, with no serious complications in the 30 days after intervention. 

Conclusion

In sum, the outcomes of this series of cases carried out in a single center indicate that high risk Impella assisted PCI is feasible and safe as preparation for TAVR in selected patients with severe aortic stenosis. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Feasibility and Safety of Impella-Assisted High-Risk PCI Before TAVR in Patients With Severe Aortic Stenosis. 

Reference: Ilhwan Yeo, el al. JSCAIhttps://doi.org/10.1016/j.jscai.2023.101061.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...